Affiliation:
1. Omsk State Medical University
Abstract
Increase intestinal permeability is one of the main mechanisms for the development of irritable bowel syndrome (IBS). The role of stress and nutrition factors is considered as key modifiable factors contributing to the development of increase intestinal permeability. Purpose of the study: to evaluate the content of a marker of increased intestinal permeability (zonulin in feces) in relation to dietary habits, levels of anxiety and depression, levels of stress hormones (cortisol in saliva) and neurotransmitters (serotonin in blood serum, dopamine in blood plasma) in patients with IBS. Materials and methods: an open cohort prospective study was conducted with the inclusion of 263 patients with an established diagnosis of IBS. The control group consisted of 40 healthy volunteers. All individuals included in the study were assessed for diet and eating habits, the severity of anxiety and depression, including the level of specific anxiety in relation to gastrointestinal symptoms, and quality of life. In addition, the levels of cortisol in the morning and evening portions of saliva, serum serotonin, plasma dopamine and fecal zonulin were assessed. Results: in patients with IBS, the marker of increased intestinal permeability (zonulin in feces) is closely related to the nature of nutrition, anxiety levels, cortisol and serotonin secretion, and is also associated with the development of abdominal pain, diarrhea, and the severity of the disease.
Publisher
LLC Global Media Technology
Subject
Gastroenterology,Hepatology
Reference60 articles.
1. Flacco M.E., Manzoli L., De Giorgio R, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986-3000. doi: 10.26355/eurrev_201904_17580.
2. Trinkley K.E., Sill B. E., Porter K., Nahata M. C. Prescribing Patterns for Outpatient Treatment of Constipation, Irritable Bowel Syndrome-Related Constipation, and Opioid-Induced Constipation: A Retrospective Cross-Sectional Study. J Manag Care Spec Pharm. 2015;21(11):1077-1087. doi: 10.18553/jmcp.2015.21.11.1077.
3. Ivashkin V.T., Maev I. V., Shelygin Yu.A., et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74-95. (In Russ.) doi: 10.22416/1382-4376-2021-31-5-74-95.@@ Ivashkin V. T., Maev I. V., Shelygin Yu. A. i dr. Diagnostika i lechenie sindroma razdrazhennogo kishechnika (Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii). Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2021;31(5):74-95. doi: 10.22416/1382-4376-2021-31-5-74-95.
4. IBS in America: Survey Summary Findings. American Gastroenterological Association. 2015. Available at: http://www.multivu.com/players/English/7634451-aga-ibs-in- america-survey/docs/survey-findings-pdf-635473172.pdf. (Accessed: 16 October 2022)
5. Abel J.L., Tayolor D. C.A. Chronic Constipation and IBS-C Treatment and Outcomes Real World Research Platform (CONTOR): A Large, Longitudinal Observational Study: 563. American Journal of Gastroenterology. 2016;111: s257. doi: 10.14309/00000434-201610001-00563.